reports
- Jonathan Moreland
PCTY PAYLOCITY HOLDING CORP.
LXRX LEXICON PHARMACEUTICALS INC.
FAF FIRST AMERICAN FINANCIAL CORPORATION
MEDP MEDPACE HOLDINGS INC.
PRU PRUDENTIAL PLC
SAH SONIC AUTOMOTIVE INC. CLASS A
MSFT MICROSOFT CORPORATION
SSTI SHOTSPOTTER
KKR KKR & CO. INC.
DKNG DRAFTKINGS INC
VERX VERTEX
DLHC INC.
FLYW DALEIGH HOLDINGS CORP
WRB FLYWIRE CORP
IE W.R. BERKLEY CORPORATION
NPWR IVANHOE ELECTRIC INC
GDV NET POWER INC
THE GABELLI DIVIDEND & INCOME TRUST
Lexicon Pharmaceuticals Inc: 1 director
A director at Lexicon Pharmaceuticals Inc bought 268,497 shares at 1.314USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financ...
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the comp...
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
TCBI TEXAS CAPITAL BANCSHARES INC.
SXI STANDEX INTERNATIONAL CORPORATION
PAYX PAYCHEX INC.
NBTB NBT BANCORP INC.
MNRO MONRO INC
LXRX LEXICON PHARMACEUTICALS INC.
LMAT LEMAITRE VASCULAR INC.
HUN HUNTSMAN CORPORATION
GME GAMESTOP CORP. CLASS A
FFIN FIRST FINANCIAL BANKSHARES INC
CR CRANE CO.
GAM GENERAL AMERICAN INVESTORS CO. INC.
ENPH ENPHASE ENERGY INC.
PCF PUTNAM HIGH INCOME SECURITIES FUND
AGYS AGILYSYS INC.
TYIA JOHNSON CONTROLS INTERNATIONAL PLC
LW LAMB WESTON HOLDINGS INC.
HWKN HAWKINS INC.
WDFC WD-40 COMPANY
HYT BLACKROCK CORPORATE HIGH YIELD FUND VI
CVCO CAVCO INDUSTRIES INC.
CRVS CORVUS PHARMACEUTICALS
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ABT ABBOTT LABORATORIES
MVBF MVB FINANCIAL CORP
THM INTERNATIONAL TOWER HILL MINES LTD
NWFL NORWOOD FINANCIAL CORP.
ZIVO ZIVO BIOSCIENCE
SONO INC.
ANIX SONOS
ETON ANIXA BIOSCIENCES
AMTB ETON PHARMACEUTICALS
JYNT AMERANT BANCORP (A)
ALLY THE JOINT
CMTV GMAC LLC
ALXO COMMUNITY BANCORP INC. VT
AZYO ALX ONCOLOGY HOLDINGS
LUMN AZIYO BIOLOGICS
BST LUMEN TECHNOLOGIES INC.
LSF BLACKROCK SCIENCE AND TECHNOLOGY TRUST
VANI LAIRD SUPERFOOD INC
BOF VIVANI MEDICAL INC
WS WI BRANCHOUT FOOD INC.
MXF WORTHINGTON STEEL
GDV THE MEXICO FUND
PMN INC.
IP THE GABELLI DIVIDEND & INCOME TRUST
CVM PROMIS NEUROSCIENCES INC.
FEAM INTER PHARMA PUBLIC COMPANY LIMITED
BDSX CEL-SCI CORPORATION
MIGI 5E ADVANCED MATERIALS INC.
BIODESIX INC
MAWSON INFRASTRUCTURE GROUP INC
Lexicon Announces Closing of Approximately $94.6 Million Public Offeri...
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the “Series B Convertible Preferred Stock”). The shares of common stock offered pursuant to the publi...
- Jonathan Moreland
SXI STANDEX INTERNATIONAL CORPORATION
LXRX LEXICON PHARMACEUTICALS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
PCF PUTNAM HIGH INCOME SECURITIES FUND
CVCO CAVCO INDUSTRIES INC.
RRBI RED RIVER BANCSHARES
ALXO ALX ONCOLOGY HOLDINGS
FRST PRIMIS FINANCIAL CORP
WRB W.R. BERKLEY CORPORATION
GAM GENERAL DE ALQUILER DE MAQUINARIA
FIG FIGMA INC.
FEAM 5E ADVANCED MATERIALS INC.
Capital Southwest Announces Financial Results for Third Fiscal Quarter...
Capital Southwest Announces Financial Results for Third Fiscal Quarter Ended December 31, 2025 DALLAS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced its financial results for the third fiscal quarter ended December 31, 2025. Third Quarter Fiscal Year 2026 Financial Highlights Total Investment Portfolio: $2.0 billion Credit P...
Capital Southwest Announces U.S. Federal Income Tax Treatment of 2025 ...
Capital Southwest Announces U.S. Federal Income Tax Treatment of 2025 Dividends DALLAS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, announced today the U.S. federal income tax treatment of its 2025 dividends. U.S. Federal Income Tax Treatment of 2025 Dividends Capital Southwest paid dividends totaling $2.56 per share that are attributable to the ta...
Standard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools Completes Sale of SomaLogic to Illumina Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy Continuing Operations on track to achieve positive adjusted EBITDA in 2026 BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced it has completed the previously announ...
Lexicon Announces Pricing of Approximately $94.6 Million Public Offeri...
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering a...
Lexicon Announces Proposed Public Offering of Common Stock
Lexicon Announces Proposed Public Offering of Common Stock THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the p...
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27,...
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain. “In its early days, Lexicon was focused on pioneering a deeper understa...
Capital Southwest Corporation Announces Formation and Launch of First ...
Capital Southwest Corporation Announces Formation and Launch of First Out Senior Loan Joint Venture DALLAS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced that it has formed a joint venture with another private credit asset manager. The joint venture will be an off-balance sheet private fund that will invest primarily in first ou...
Capital Southwest Announces Hiring of Managing Director
Capital Southwest Announces Hiring of Managing Director DALLAS, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, is pleased to announce the hiring of Ryan Mullins as its newest Managing Director. “I am pleased to welcome Ryan to Capital Southwest and excited to have another experienced deal originator joining our team,” stated Josh Weinstein, Chief Inve...
Greene County Bancorp, Inc. Announces Cash Dividend
Greene County Bancorp, Inc. Announces Cash Dividend CATSKILL, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Greene County Bancorp, Inc. (NASDAQ-GCBC) today announced that its Board of Directors has approved a quarterly cash dividend of $0.10 per share on the Company’s common stock. The dividend reflects an annual cash dividend rate of $0.40 per share, which is the same rate as the dividend declared during the previous quarter. The cash dividend for the quarter ended December 31, 2025, will be paid to shareholders of record as of February 13, 2026, and is expected to be paid on February 27, 202...
Greene County Bancorp, Inc. Delivers Net Income of $10.3 Million for t...
Greene County Bancorp, Inc. Delivers Net Income of $10.3 Million for the Quarter Ended December 31, 2025, the Highest Quarterly Earnings in the Bank’s 137-Year History CATSKILL, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Greene County Bancorp, Inc. (the “Company”) (NASDAQ: GCBC), the holding company for the Bank of Greene County and its subsidiary Greene County Commercial Bank, today reported net income for the three and six months ended December 31, 2025, which is the second quarter of the Company’s fiscal year ending June 30, 2026. Net income for the three and six months ended December 31,...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting wi...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain – No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the ...
Capital Southwest Announces Preliminary Estimate of Third Quarter 2026...
Capital Southwest Announces Preliminary Estimate of Third Quarter 2026 Operating Results and Earnings Release and Conference Call Schedule DALLAS, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, is pleased to announce its preliminary operating results for the third quarter of its 2026 fiscal year (quarter ended December 31, 2025) and its third quarter 2026 earnings relea...
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the...
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA resubmission and potential approval in 2026 Company presentation January 15 at 12:00 p.m. PT (3:00 p.m. ET) THE WOODLANDS, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a business and pipeline update at...
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access...
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” -White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to support millions of Americans suffering from chronic pain- THE WOODLANDS, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In October 2025, (Nasdaq: LXRX) convened an in-person Roundtable in Washington, D.C., to better understand the unmet needs of people living with chronic pain and id...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.